Lidocaine Spray vs Viscous Lidocaine Solution Plus Lidocaine Spray in Patients Undergoing Non-Sedated EGD

Launched by SAWANPRACHARAK HOSPITAL · Dec 15, 2023

Keywords

ClinConnect Summary

A randomized controlled trial was conducted between July and October 2023 at Sawanpracharak hospital, Thailand. Of 250 patients undergoing UGE, 125 were randomly assigned to group S (lidocaine spray alone) and 125 to group S+V (lidocaine spray plus lidocaine viscous solution). The total dose of lidocaine did not exceed 5 mg/kg in both groups

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients scheduled for upper gastrointestinal endoscopy:
• • Patients who are robust, without chronic illnesses, or with controlled chronic conditions that do not adversely affect the function of any organ (American Society of Anesthesiologists (ASA) physical status classification I-II).
• Exclusion Criteria:
• • Has a history of receiving painkillers or sleeping pills within 24 hours before the endoscopy.
• • Has a history of post-endoscopy nausea and vomiting.
• • Patients who have undergone upper gastrointestinal endoscopy previously.
• • Has chronic conditions such as epilepsy, vertigo, or mental health disorders.
• • Has a history of allergy to anesthesia used in the study.
• • Pregnant or currently breastfeeding.
• • Refuses to participate in the study.